Christopher J.P. Velis
Chairman & CEO
Mr. Velis has spent more than 20 years as an investment banker, consultant, and venture investors in medical technology. With such deep roots in the global med tech industry, Mr. Velis provides clients with a unique level of access to strategic buyers and capital sources, shepherding deals to successful conclusions. Having represented more than 150 medical device mergers and venture investments, he has brokered a wide array of transactions including licensing agreements, joint venture partnerships and mergers and acquisitions, and exit strategies.
Prior to founding MedCap Advisors, Mr. Velis was a partner, board member and managing director in charge of investment banking at HealthpointCapital. He was previously head of medical technology investment banking at Brown Brothers Harriman, a partner at Mirus Capital advisor and began his career in corporate finance at Merrill Lynch.
Thomas J. Duquette
Managing Director of Investment
Banking & Private Placements
Mr. Duquette is responsible for client support at MedCap Advisors. His duties include growing, developing and managing our network of investors, clients and industry contacts, providing project leadership for private placements, and assisting in research and valuation analysis. Mr. Duquette’s approach to helping clients involves learning their specific needs and deploying the best resources to create the optimal solution.
Prior to joining MedCap Advisors, Mr. Duquette enjoyed 16 years of work at Bear Stearns & Co. There he served as Associate Director, Private Client Services, and was head of client service on a team with the co-founder of Bear Stearns’ Wealth Management Services division. His expertise includes investment banking, private placements, merchant banking, institutional equities, block trading, control stock, derivatives, hedging, wealth management, and trust/estate planning.
Edward Ahn, Ph. D.
Managing Director and Chief Science Officer
Dr. Ahn most recently served as Vice President of Biologics Product Development for Pioneer® Surgical Technology, Inc. and its newly formed biologics division. He successfully developed and launched novel synthetic bone grafts, allograft-based tissue products and structural calcium phosphate nanotechnology in interbody spinal fusion.
Dr. Ahn earned his B.S.in Chemical Engineering from Stanford University and M.S. in Chemical Engineering Practice and Ph.D. in Chemical Engineering from MIT. Presently he is a senior lecturer at Harvard University’s School of Engineering and Applied Science, and is the Vice-Chairman of the MIT Enterprise Forum of Cambridge. He is also a member of the Scientific Advisory Board of the Center of Innovation for Nanobiotechnology (COIN) and a principal of First Founders, Ltd., a not-for-profit corporation dedicated to building young business ventures emerging from academic and other institutional research.